STUDY | Real-world treatment patterns in third-line therapies for RRMM across Europe

Total multi-country cohort (N = 1,865)

Countries included:

Germany (n = 276) | **Italy** (n = 289) | **UK** (n = 401)
New data (n = 197)
Historical (n = 204) | **France** (n = 527)
New data (n = 129)
Historical (n = 398) | **Spain** (n = 372)
New data (n = 133)
Historical (n = 239)

STUDY DESIGN

Retrospective, multi-country cohort study evaluating treatment patterns in patients with RRMM initiating third-line therapies.

Germany and Italy	**UK, France, and Spain**
2016–2020	Historical data collected: 2016–2018
New data collected: 2019–2021

TREATMENT PATTERNS

**Most common class of drug used across all countries: IMiDs**

Characteristics of patients with RRMM who initiated third-line therapy

	Germany	Italy	UK	France	Spain
Median age	75	73	71	72	70
Prior MM treatments %					
PI	95.7	52.2	97.8	88.6	93.5
IMiD	55.8	73.7	93.3	92.6	82.5
SCT	27.2	14.9	41.9	44.2	40.6

Most common third-line treatment regimen by country

12.8%	18.0%	67.5%	17.1%	15.0%
Germany
Rd	Italy
Rd	UK
IRd	France
Pd	Spain
DVd

Change in most common third-line treatment regimen (historical → new)

	Historical (2016–2018)		New (2019–2021)
UK	**36.3**% Rd	→	**67.5**% IRd
France	**33.9**% Pd	→	**17.1**% Pd
Spain	**19.7**% Rd	→	**15.0**% DVd

Incidence of re-treatment with same drug class by country

IMiD retreatment | PI retreatment

	IMiD retreatment	PI retreatment
Germany	42.9%	97.6%
Italy	83.3%	76.1%
UK	93.2%	100.0%
France	92.3%	92.3%
Spain	83.1%	97.0%

The treatment patterns for third-line therapies for multiple myeloma vary significantly across countries within Europe. However, there has been a trend toward triplet regimens and anti-CD38 use in later lines of treatment.

Abbreviations: DVd, daratumumab-bortezomib-dexamethasone; IMiD, immunomodulatory drug; IRd, ixazomib-lenalidomide-dexamethasone; MM, multiple myeloma; Pd, pomalidomide-dexamethasone; PI, proteasome inhibitor; Rd, lenalidomide-dexamethasone; RRMM, relapsed/refractory multiple myeloma; SCT, stem cell transplantation.

MultipleMyelomaHub | Brought to you by **Scientific Education Support**